原始单价 mRNA 疫苗对儿童和青少年 COVID-19 奥密克戎相关住院保护效果的持久性——美国,2021-2023 年
在 2021 年 12 月 19 日至 2023 年 10 月 29 日期间,Overcoming COVID-19 网络采用病例对照设计,评估了 5-18 岁美国儿童和青少年中 ≥2 剂原始单价 COVID-19 mRNA 疫苗对 COVID-19 相关住院和重症的保护效果(VE)。最近一剂接种后 <120 天住院的 VE 为 52%(95% CI = 33%-66%),120-364 天为 19%(95% CI = 2%-32%);对重症的 VE 分别为 57%(95% CI = 21%-76%)和 25%(95% CI = -9% to 49%)。数据支持 CDC 建议所有儿童和青少年接种更新版 COVID-19 疫苗。
要点
- 最近一剂原始单价 mRNA 疫苗接种后 <120 天,对 COVID-19 相关住院的 VE 为 52%(95% CI = 33%-66%)。
- 接种后 120-364 天,对 COVID-19 相关住院的 VE 降至 19%(95% CI = 2%-32%)。
- 对重症 COVID-19 的 VE 在 <120 天为 57%(95% CI = 21%-76%),120-364 天为 25%(95% CI = -9% to 49%)。
核心结论
- 由于接种更新版 COVID-19 疫苗的儿童比例低且原始单价疫苗保护效果减弱,这些数据支持 CDC 建议所有儿童和青少年接种更新版 COVID-19 疫苗以预防重症 COVID-19。
研究设计与样本
- 2021 年 12 月 19 日至 2023 年 10 月 29 日期间,Overcoming COVID-19 网络采用病例对照设计,评估 5-18 岁美国儿童和青少年中 ≥2 剂原始单价 COVID-19 mRNA 疫苗对 COVID-19 相关住院和重症的保护效果(VE)。
- 接种二价或更新版单价疫苗的儿童和青少年人数太少,无法单独评估其效果。
主要发现
- 大多数病例患者(SARS-CoV-2 检测阳性者)未接种疫苗,尽管报告与重症 COVID-19 相关的基础疾病频率很高。
- 最近一剂接种后 <120 天住院的 COVID-19 相关住院 VE 为 52%(95% CI = 33%-66%),120-364 天为 19%(95% CI = 2%-32%)。
- 最后一剂在之前一年内任何时间接种的 COVID-19 相关住院 VE 为 31%(95% CI = 18%-43%)。
- 最近一剂接种后 <120 天住院的重症 COVID-19 VE 为 57%(95% CI = 21%-76%),120-364 天为 25%(95% CI = -9% to 49%),最后一剂在之前一年内任何时间接种为 38%(95% CI = 15%-55%)。
- 排除有记录的免疫抑制状况的儿童和青少年后,VE 相似。
临床怎么用
- 这些数据支持 CDC 建议所有儿童和青少年接种更新版 COVID-19 疫苗以预防重症 COVID-19。
局限性
- 接种二价或更新版单价疫苗的儿童和青少年人数太少,无法单独评估其效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pediatric COVID-19 vaccination is effective in preventing COVID-19-related hospitalization, but duration of protection of the original monovalent vaccine during SARS-CoV-2 Omicron predominance merits evaluation, particularly given low coverage with updated COVID-19 vaccines. During December 19, 2021-October 29, 2023, the Overcoming COVID-19 Network evaluated vaccine effectiveness (VE) of ≥2 original monovalent COVID-19 mRNA vaccine doses against COVID-19-related hospitalization and critical illness among U.S. children and adolescents aged 5-18 years, using a case-control design. Too few children and adolescents received bivalent or updated monovalent vaccines to separately evaluate their effectiveness. Most case-patients (persons with a positive SARS-CoV-2 test result) were unvaccinated, despite the high frequency of reported underlying conditions associated with severe COVID-19. VE of the original monovalent vaccine against COVID-19-related hospitalizations was 52% (95% CI = 33%-66%) when the most recent dose was administered <120 days before hospitalization and 19% (95% CI = 2%-32%) if the interval was 120-364 days. VE of the original monovalent vaccine against COVID-19-related hospitalization was 31% (95% CI = 18%-43%) if the last dose was received any time within the previous year. VE against critical COVID-19-related illness, defined as receipt of noninvasive or invasive mechanical ventilation, vasoactive infusions, extracorporeal membrane oxygenation, and illness resulting in death, was 57% (95% CI = 21%-76%) when the most recent dose was received <120 days before hospitalization, 25% (95% CI = -9% to 49%) if it was received 120-364 days before hospitalization, and 38% (95% CI = 15%-55%) if the last dose was received any time within the previous year. VE was similar after excluding children and adolescents with documented immunocompromising conditions. Because of the low frequency of children who received updated COVID-19 vaccines and waning effectiveness of original monovalent doses, these data support CDC recommendations that all children and adolescents receive updated COVID-19 vaccines to protect against severe COVID-19.
引用
- Zambrano LD, Newhams MM, Simeone RM, et al. Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron-Associated Hospitalization in Children and Adolescents - United States, 2021-2023. MMWR Morb Mortal Wkly Rep. 2024. PMID: 38635481. doi:10.15585/mmwr.mm7315a2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。